CALGARY, Alberta, Jan. 26, 2010 (GLOBE NEWSWIRE) -- Liberty Analytics Co., a leading provider of large ,small - and micro-cap independent investment research, today initiated coverage on Keryx Biopharmaceuticals, Inc.(Nasdaq:KERX) . Liberty Analytics is currently offering a complimentary trial subscription. To view our research go to:

About LAC:

Liberty Analytics Co. is a leading provider of independent investment research in North America. Our services include research analysis on the large, small- and micro-cap markets, real-time news and financial data, market commentary and the LAC newsletter. Liberty Analytics' staff of large and small-cap investment professionals is dedicated to providing the market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to and click on the complimentary trial subscription button on our home page, or go directly to our registration page at

About Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX)

Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease.

LAC Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Liberty Analytics has not been compensated by any of the above mentioned companies. Please read our report and visit our Web site,, for complete risks and disclosures.

Liberty Analytics
Kevin Mix